

BIC-TAF-FTC vs. DTG-ABC-3TC as Initial Therapy
GS-1489

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy

GS-1489: Design

GS-1489: Study Design

- **Background:** Randomized, double-blind, active-controlled, phase 3 study evaluating the efficacy and safety of bicitegravir-tenofovir alafenamide-emtricitabine versus dolutegravir-abacavir-lamivudine for treatment-naïve individuals
- **Inclusion Criteria**
 - Age ≥ 18
 - Antiretroviral-naïve (or ≤ 10 days of treatment)
 - HIV RNA ≥ 500 copies/mL
 - eGFR ≥ 50 mL/min
 - HLA B*5701 negative
 - No chronic HBV infection
- **Regimens**
 - Bicitegravir-TAF-FTC (50/200/25 mg)
 - Dolutegravir-ABC-3TC (50/600/300 mg)

Bicitegravir-TAF-FTC

(n = 314)


Dolutegravir-ABC-3TC

(n = 315)

BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy

GS-1489: Results

Week 48 Virologic Response (Intention-to-Treat Analysis)




BIC-TAF-FTC versus DTG-ABC-3TC as Initial Therapy

GS-1489: Results

Treatment Emergent Adverse Events in Study 1489 (AE's >5%) Through Week 48		
	Bictegravir-TAF-FTC (n = 314)	Dolutegravir-ABC-3TC (n = 315)
Diarrhea, %	12.7	13.0
Headache, %	11.5	13.7
Nausea, %	10.2	22.9
Fatigue, %	6.1	8.6
Arthralgia, %	3.5	6.0
Insomnia, %	4.5	6.3*
Change in eGFR (mL/min)	-10.5	-10.8


BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy Study 1489: Results

Change in Markers of Proximal Tubulopathy at 48 Weeks




BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-1489: Results

Change in Bone Mineral Density at 48 Weeks



BIC-TAF-FTC versus DTG-ABC-3TC for Initial Therapy GS-1489: Results

Change Lipids at 48 Weeks



Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.

